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Background: The prevalence of overweight and obesity is increasing, and it has been 
estimated that 39% of the world’s population is above normal weight. This is worrisome as 
both overweight and obesity is causally linked to a wide range of chronic diseases and 
effective strategies to achieve and maintain weight loss are therefore needed. In order to lose 
weight, one has to be in a negative energy balance over time. This can be achieved through a 
variety of diets, but no single strategy has been shown to be superior on average. However, 
substantial inter-individual variation in the weight loss response to different diets has been 
demonstrated. Identifying biological factors which may predict who will respond to a given 
diet therefore has the potential to improve our understanding and treatment of overweight and 
obesity.  
 
The peroxisome proliferator-activated receptor α (PPARα) is an important regulator of energy 
metabolism and specifically increases the metabolism of fat upon activation. Thus, 
endogenous PPARα-activity may be a key factor influencing the response to diets differing in 
fat content. The aim of this study was therefore to determine whether baseline plasma 
concentrations of metabolites related to one-carbon metabolism and B-vitamin status, of 
which some have been suggested as potential biomarkers of PPARα-activity, was associated 
with weight loss and moreover could predict inter-individual differences in the weight loss 
response to two diets with very different fat- and carbohydrate content. We further 
hypothesized that the metabolites suggested to reflect endogenous PPARα-activity would be 
similarly associated with weight loss response to the diets. 
 
Methods: For a period of 12 weeks, 46 men with obesity between the ages of 30-50 years old 
were randomly allocated to either following a low-fat, high-carbohydrate diet (LFHC) or a 
very-high fat, low-carbohydrate diet (VHFLC). Both diets were equal in terms of protein and 
energy content. Measurements of body weight as well as fasting blood samples were collected 
at baseline and every study visit. Baseline plasma metabolite concentrations were determined 
by gas- and liquid chromatography coupled to tandem mass spectrometry or microbiological 
assay. The overall association between baseline metabolite concentrations and subsequent 
weight loss were assessed by calculating Spearman correlations with weight change in % at 
12 weeks. To visualize the association between baseline metabolite concentration and weight 
loss, weight loss in % from baseline to 12 weeks was plotted against the metabolite 
 
concentrations at baseline. The individuals were coloured according to diet group, and linear 
regression lines extrapolated to the range of the metabolites were superimposed on the plot to 
visualize trends within the diet groups. To formally test the potential interaction between the 
baseline metabolite concentrations and the diets, an interaction term was added to a linear 
regression analysis comparing body weight at week 12, adjusted for baseline body weight. 
 
Results: We did not observe strong associations between baseline plasma metabolite 
concentrations and weight loss. However, we did observe some differential trends in weight 
loss response according to baseline plasma metabolite concentrations and diet type. 
Specifically, we observed that the LFHC-diet outperformed the VHFLC-diet for lower 
baseline concentrations of homocysteine, sarcosine, N1-methylnicotinamide (mNAM), 
pyridoxal (PL), pyridoxal-5-phospate (PLP), 4-pyridoxic acid (PA) and methylmalonic acid 
(MMA) and for higher concentrations of cystathionine, betaine, dimethylglycine (DMG), 
glycine and folate. The VHFLC-diet on the other hand was observed to produce the superior 
result when concentrations of glycine were lower and for higher concentrations of 
homocysteine, sarcosine, mNAM, PL, PLP, PA and MMA. However, the formal tests for 
interaction between baseline metabolite concentrations and diet type were inconclusive. Of 
the metabolites previously suggested to reflect PPARα-activity, we observed that mNAM, PL, 
PLP and MMA demonstrated similar trends in terms of which diet was more effective 
according to higher or lower concentrations, but glycine and DMG demonstrated opposite 
trends.  
 
Conclusion: In this study, metabolites related to one-carbon metabolism and markers of B-
vitamin status at baseline was not strongly associated with weight loss. However, some 
differential trends were observed in the weight loss response to the different diets. Of the 
metabolites suggested to reflect PPARα-activity, somewhat conflicting associations were 
seen. Nevertheless, some of these metabolites may have potential in identifying individuals 
who would benefit from each diet and may therefore potentially be of value when considering 
individual dietary advice for weight loss. To further explore whether any of these metabolites 
can be used to tailor dietary weight loss advice to the individual, a first step should be to 
perform similar studies in other existing dietary intervention trials, preferably with larger 
sample sizes. From there, the most promising metabolites should ultimately be tested in 
randomized controlled trials to determine whether, and how, stratification by metabolites 
according to baseline concentration can be utilized for personalized nutrition.   
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1 Introduction  
 
1.1 Overweight and obesity  
Globally, overweight and obesity has increased substantially during the past decades. In fact, 
between 1975 and 2016, the prevalence of obesity almost tripled. In 2016, 1.9 billion adults 
met the criteria of being overweight and of these about 650 million met the criteria of being 
obese, corresponding to 39% of the world’s adult population being above normal weight (1). 
This has made the World Health Organization (WHO) recognize overweight and obesity as a 
global epidemic that poses an important public health challenge (2). Similarly, in Norway it 
has been estimated that 61.7 % of the adult population suffer from overweight whereof 23.1 
% suffer from obesity (3). Both overweight and obesity can be defined as an excessive 
accumulation of fat that may impair health (1). The striking increase in people suffering from 
overweight and obesity is worrisome as both are associated with increased risk of other 
chronic diseases such as diabetes, cardiovascular diseases, different types of cancers and 
osteoarthritis (1). Moreover, 2.8 million annual deaths can be attributed to overweight and 
obesity (4). Overweight and obesity also impose a rather large economic burden as the global 
economic impact of obesity was estimated to be 2.0 trillion US dollars in 2014 (5). In light of 
the negative consequences of overweight and obesity, it is important to find effective 
strategies to reverse this negative development.  
 
1.2 Measuring and classification of overweight and obesity 
Overweight and obesity are most commonly defined by body mass index (BMI, kg/m2). BMI 
is an easy tool to use for this purpose as it only requires the height and weight of a person to 
get an estimate of whether the person is underweight, normal weight, overweight or obese. 
WHO defines overweight as a BMI equal to or greater than 25, and obesity as a BMI equal to 
or greater than 30 (1). In addition to BMI, waist circumference is often used as an additional 
measure to assess whether an individual is at risk for metabolic syndrome, cardiovascular 
disease or diabetes type 2, and WHO has defined waist circumference cut-off points for the 
risk of developing these diseases (6-8). A waist circumference above 80 cm for women and 
94 cm for men is associated with increased risk of developing diabetes type 2 and 
cardiovascular disease, and a waist circumference above 88 cm for women and 102 cm for 
men is associated with an even higher risk of developing these diseases (6). There are also 
other tools that can be used to identify overweight and obesity and to evaluate body 
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composition. These methods include double indirect methods such as skinfold measurements 
and bioelectric impedance analysis and indirect methods such as total body water, dual-
energy X-ray absorptiometry, computed tomography and magnetic resonance imaging (9). 
However, several of these tools have limited use in overweight and obese individuals due to 
body size limitations related to the machines or the methods are not well enough developed to 
assess individuals with overweight and obesity (10).  
 
1.3 Energy balance and the causes of overweight and obesity  
 
1.3.1 Definition of energy balance and energy intake 
When discussing overweight and obesity, the concept of energy balance is particularly 
relevant. Energy balance can be defined as “The physiological state in which daily energy 
intake equals energy expenditure and both body weight and energy content (defined by body 
composition) are constant” (7). Energy balance can thus be represented by an equation 
consisting of energy intake on the one side and energy expenditure on the other side and 
where imbalances in this equation over time will lead to changes in energy storages. The 
intake of energy comes from the food and drinks we consume which contains energy in the 
form of fat, carbohydrates including dietary fibre, protein and to a lesser extent alcohol (11). 
In the context of energy balance, energy intake more specifically refers to the amount of 
energy absorbed, not energy eaten. However, the difference between energy consumed and 
energy absorbed, due to incomplete digestion and absorption, is usually negligible (12).  
 
1.3.2 Energy expenditure 
The three main components that make up energy expenditure are basal metabolic rate (BMR), 
diet-induced thermogenesis (DIT) and physical activity (7). BMR is the energy cost of 
maintaining homeostasis and vital body functions while at rest and comprises roughly two-
thirds of daily energy expenditure (7, 12). BMR is also positively correlated to body mass, 
and especially to the amount of fat-free mass (7, 11). Furthermore, energy is also required in 
order to digest, absorb and metabolize the foods consumed and this is referred to as DIT. The 
DIT of the different macronutrients vary, however it has been estimated that DIT comprises 
about 10% of daily energy expenditure in individuals who consume a varied diet and are in 
energy balance (7, 13). Energy expenditure from physical activity not only include physical 
exercise, but all bodily movements produced by skeletal muscle which results in the 
expenditure of energy (14). Physical exercise is a subcategory of physical activity and can be 
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defined as a planned and structured activity with a goal of maintaining or improving physical 
fitness or function (14). Nevertheless, physical activity is the component of energy 
expenditure that varies the most among individuals and to the greatest degree can be modified 
as it is highly dependent on a person’s behaviour.  
 
1.3.3 Energy storage 
Energy balance is reflected in the body’s energy storages and an imbalance between energy 
intake and energy expenditure over time ultimately leads to either an increase or a decrease in 
the body’s total energy stores depending on whether the energy balance points in a positive or 
negative direction. The body energy stores refer to the energy reserves of fat, carbohydrate 
and protein stored in muscle- and fat tissue as well as in glycogen storages in the body. 
Glycogen can be referred to as our short-term storage of energy in the form of multibranched 
chains of glucose and is mainly stored in the liver (∼100 g) and muscle tissue (∼400 g) to 
provide easily accessed energy when needed (12, 15). However, the body has limited capacity 
to store energy in the form of glycogen. Thus, when energy intake exceeds energy 
expenditure over time, the excess energy beyond what the body can store as glycogen will 
therefore be stored as fat in adipose tissue (12). Adipose tissue is the body’s largest energy 
storage and 1 kg of body fat contains to approximately 7000 kcal whereas 1 kg of muscle 
mass corresponds to about 1200 kcal (12). Although body weight may fluctuate 
independently of energy balance, primarily due to short-term fluctuations in hydration status, 
long term changes in the energy stores will ultimately lead to corresponding changes in body 
weight (12).  
 
1.3.4 The causes to overweight and obesity 
As described, overweight and obesity are caused by a positive energy balance over time. 
However, the underlying factors contributing to a positive energy balance are many and 
complex. One of the factors that has been highlighted as an important contributor is the global 
shift towards an increased availability, promotion and intake of energy dense foods with high 
contents of sugars and fats (1). Furthermore, reduced energy expenditure following a decrease 
in physical activity as a result of increased urbanization and less labour-intensive work, is 
another contributing factor, as being physically active has become more dependent on a 
person’s intentional behaviour (1, 16). Studies have also investigated whether hormones 
related to appetite regulation may contribute to the development of overweight and obesity in 
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terms of driving excessive food intake. Findings indicate an association between obesity and 
reduced postprandial response of satiety hormones such as glucagon-like peptide 1 and 
peptide YY in addition to hormones promoting hunger such as ghrelin, which favours 
excessive energy intake (17). However, because most of the studies have measured the 
difference in these hormones between overweight or obese and normal weight individuals, it 
is not possible to distinguish whether postprandial reductions in these hormones contribute 
causally to the development of overweight and obesity or result from being overweight or 
obese (17). The role of genetics and their potential influence in the development of 
overweight and obesity has also been increasingly studied over the past years. Several 
obesity-related gene variants have been identified, however with the exception of a few rare 
single genetic variants causing monogenic obesity, it was reported that these gene variants 
were only able to explain about 6% of the variation in BMI in the general population until 
recently (18). However, recent studies report that the proportion of variation in BMI 
explained by genetic traits in the general population might be as high as 40% (19). 
 
1.4 Negative health effects of overweight and obesity 
Overweight and obesity can have negative health impacts and are causally linked to increased 
morbidity and mortality. About 70% of patients with diabetes type 2 are overweight, and the 
risk of developing diabetes type 2 increases with increasing overweight (20). Overweight is 
also associated with elevated blood lipids and hypertension, and thus increases the risk of 
developing cardiovascular diseases such as coronary heart disease (21, 22). Furthermore, 
overweight and obesity are also associated with conditions affecting the musculoskeletal 
system such as osteoarthritis which causes joint degeneration and consequently dysfunction 
and pain related to affected areas (23). Obesity has been found to be a significant risk factor 
for both the development and progression of osteoarthritis of the knee and a less strong 
association has been found between obesity and osteoarthritis of the hip. Proposed 
explanations include the increased mechanical stress to the joints due to increased body 
weight, as well as alterations in the growth and structure of tissues due to increased synthesis 
of endocrine factors following expansion of the adipose tissue (23).  
 
Overweight may also increase the risk of certain types of cancer such as breast cancer, 
endometrial cancer, prostate cancer and cancers in the colon among others (24). The 
pathophysiology is not fully understood, but one possible underlying mechanism may be 
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related to the increased production of various hormones that may stimulate cell differentiation 
and growth. For example, people suffering from overweight often have elevated blood 
concentrations of insulin- and insulin-like growth factors and these hormones may help 
stimulate the development of cancer tumours (24). Furthermore, people with overweight often 
have a chronic low-grade inflammation which may also increase the risk of developing cancer 
(24). Overweight and obesity not only increase the risk of physical diseases but can also affect 
mental health. In this regard, overweight and obesity have been associated with low self-
esteem, body-image dissatisfaction, depression and eating disorders such as binge-eating 
disorder among others (25, 26). Furthermore, the society’s idealization of leanness and weight 
stigmatization towards overweight and obese individuals has been identified as contributing 
factors to the above mentioned damaging psychological consequences associated with 
overweight and obesity (27).  
 
1.5 Health effects of weight loss 
Weight loss is recommended for individuals with overweight and obesity to improve health 
and reduce the likelihood of developing obesity-related comorbidities. The goal however 
doesn’t necessarily have to be to achieve what is defined as a normal weight or BMI. As a 
matter of fact, a modest weight loss of 5-10% of total body weight has been shown to be 
beneficial for individuals struggling with overweight and obesity as it improves metabolic 
health and reduces the risk of developing metabolic syndrome (28). A weight loss of 5-10% 
of initial body weight has also been found to improve cardiovascular risk factors such as 
glycated haemoglobin (HbA1c), blood pressure and blood lipids among overweight and obese 
individuals (29). These findings indicate that encouraging individuals with overweight and 
obesity to lose 5-10% of their body weight may have profound health effects. In addition, it 
may be easier to motivate individuals to lose 5-10% of their body weight rather than striving 
to reach a BMI corresponding to normal weight.  
 
1.6 Weight loss diets  
In order for a diet to be effective for weight loss it has to lead to a negative energy balance 
over time and a variety of diets can be used to achieve this. Some diets limit certain 
macronutrients while other diets limit certain types of foods. Low-carbohydrate, high-fat diets 
such as the Atkins diet limit the intake of carbohydrates with focus on high energy intakes 
from fat (30). On the other hand, low-fat diets such as the DASH diet usually limits the 
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energy intake of fat to 20-35% of total energy intake and consists of higher amounts of 
carbohydrates (30). Very-low-fat diets further limit the intake of fat to under 20% of total 
energy intake, and examples are the Pritikin and Ornish diets (30). However, these diets 
ultimately work through the same mechanism, by creating an energy deficit, and no single 
strategy has been shown to be superior on average (31, 32). Moreover, long term weight loss 
maintenance has proven to be difficult irrespective of the type of diet as many dieters regain 
most of the lost weight within a short period of time (33-35). This is troublesome as it 
indicates that weight loss diets on average are not very effective in weight maintenance which 
should be the ultimate measure of weight loss success.  
 
At the same time, solely focusing on average weight loss in dietary intervention studies might 
lead to a masking of the individual variability in response to dietary interventions (33). For 
example, a study investigating the effect of a low-fat diet compared to a low-carbohydrate 
diet found similar average weight loss effects in both groups, however there was a large inter-
individual variation in the response to both diets with some participants losing 30 kg whereas 
others gained 10 kg during the study period (36). Similar inter-individual variations in weight 
loss response to diets differing in macronutrient content has also been reported in other 
dietary intervention studies (37, 38). Inter-individual differences in weight loss success can of 
course to a certain degree be attributed to individual differences in adherence to the diets, and 
higher self-reported dietary adherence has been associated with greater weight loss (39). On 
the other hand, there might be other factors influencing the weight loss response to dietary 
interventions such as individual differences in genetics, metabolism, gut microbiota or 
adaptive thermogenesis among others (40, 41). A better understanding and identification of 
individual characteristics or factors which may cause individuals to respond differently to 
dietary interventions can therefore have tremendous potential in terms of guiding individuals 
to choose the most effective weight loss strategy for them. Personalized nutrition is a field 
that seeks to identify such factors and the interest and research in this field of nutrition is 
increasing.  
 
1.7 Personalized nutrition 
The nutritional recommendations issued to the general population in today’s society is to a 
certain extent based on the idea that one diet is healthiest and works best for all. However, 
this approach does not take into account the above mentioned often-observed inter-individual 
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variation in response to dietary interventions. Personalized nutrition on the other hand is an 
approach which seeks to tailor nutritional recommendations based on individual 
characteristics or traits. The personalization of nutritional recommendations and advice can 
however be viewed as occurring at different levels (42). One of the simplest forms of 
personalized nutrition is stratified nutrition where the general nutritional guidelines are 
tailored to subgroups in the population based on determinants such as gender or age (42). 
More individualized approaches of personalized nutrition are based on the addition of 
phenotypic information through for example anthropometrical measurements (BMI, waist 
circumference etc.), metabolic or biochemical analysis or measurements of physical activity 
(42). Another and perhaps the most individualized type of personalized nutrition is directed 
around the identification of genetic variants which impact individuals’ response to foods or 
nutrients (42). Ultimately, the end goal in personalized nutrition is to be able to provide 
tailored nutritional advice to each specific individual based on phenotypical and genotypical 
traits as well as lifestyle, environmental and metabolic factors (43). Different technologies are 
being used to identify factors which may contribute to explaining the inter-individual 
variation in response to dietary interventions. One such method is metabolomics.  
 
1.7.1  The use of metabolomics in personalized nutrition  
Metabolomics refer to the quantitative analysis of small molecules, such as metabolites found 
in the circulation (44). Global metabolomics aim to quantify all small molecules, while 
targeted metabolomics focus on smaller sets of metabolites which are often related to each 
other (44). Metabolomics in the context of personalized nutrition provides knowledge on how 
foods are metabolized, and more specifically how individuals can metabolize the same type of 
foods differently. The use of food-derived biomarkers is one way of distinguishing how 
different individuals metabolize the same type of foods differently, and these biomarkers or 
metabolites can further provide insights into how foods can impact the health of different 
individuals (43). Moreover, metabolomics can also be used to group individuals with similar 
metabolic profiles, referred to as metabotyping or metabolic profiling, which in turn provides 
opportunities to issue more precise and personalized nutritional advice to groups with similar 
metabolic traits (43, 45). The use of metabolomics may also provide opportunities in terms of 
being able to differentiate between responders and non-responders to nutritional interventions.  
 
Applying metabolomics and biomarkers to investigate their ability to predict weight loss 
response to diets has not been extensively researched to date. However, some studies have 
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applied targeted metabolomics to identify biomarkers or metabolites which may be used for 
this purpose (46-49). One study found that fasting baseline levels of acetoacetate, 
triacylglycerols, phosphatidylcholines, specific amino acids, creatine and creatinine could 
contribute to explain some of the variation in weight loss success following a low-calorie diet. 
It was reported that these metabolites potentially could be used to predict weight loss response 
in morbidly obese individuals (46).  
 
The use of glycaemic markers as predictors of weight loss response to different diets has also 
been investigated. One study measured baseline fasting plasma glucose and reported that 
participants with normal glucose tolerance lost more weight following a low-fat, high-
carbohydrate diet whereas individuals with reduced glucose tolerance had a more beneficial 
weight loss response following a high-fat, low-carbohydrate diet (47). Another study 
investigated whether insulin sensitivity could predict the effectiveness of a low-fat, high-
carbohydrate diet and a high-fat, low-carbohydrate diet for weight loss. Similarly to the 
previous study, it was reported that insulin sensitive individuals lost more weight following a 
low-fat, high-carbohydrate diet whereas insulin resistant individuals lost more weight following 
a high-fat, low-carbohydrate diet (48). A third study investigated whether measuring both 
fasting glucose and insulin at baseline could predict the most effective diet for weight loss in 
individuals with obesity following either a low-fat, high-carbohydrate diet or a high-fat, low-
carbohydrate diet. In this study however, it was reported that among individuals with reduced 
glucose tolerance, those with high-fasting insulin lost more weight following a low-fat, high-
carbohydrate diet whereas those with low-fasting insulin lost more weight following a high-fat, 
low-carbohydrate diet (49). In light of the two other previous studies using glycemic markers, 
the findings of this study might thus suggest that there might be additional sub-groups among 
those with reduced glucose tolerance which may respond differently depending on whether 
fasting insulin is high or low. In summary, these studies illustrate the potential and possibilities 
of giving dietary advice based on biomarkers, but also the complexity as there might be sub-
groups within the sub-groups who might respond differently. However, it has to be noted that 
the findings of the first and last-mentioned study using glycemic status as a predictor of weight 
loss response were based on retrospective statistical analyses of previous randomized controlled 
studies and participants were not given dietary advice based on their glycemic status.  
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1.8 One-carbon metabolism and B-vitamin status 
The one-carbon metabolism refers to the metabolic reactions where one-carbon units are 
transferred between different compounds. In one-carbon metabolism, different molecules can 
act as methyl donors or methyl acceptors, meaning that they either donate or bind a methyl-
group. Central metabolic pathways in the one-carbon metabolism are the methionine-
homocysteine cycle, the transsulfuration pathway, the folate cycle and the choline oxidation 
pathway. An overview of these pathways is presented in Figure 1.  
 
 
Figure 1. An overview of central metabolic pathways in one-carbon metabolism.  
A) The folate cycle, B) the methionine-homocysteine cycle, C) the transsulfuration 
pathway and D) the choline oxidation pathway. The metabolites shown in bold text as well 
as the B-vitamin cofactors shown in black circles are of relevance to this thesis. The enzymes 
are presented in grey boxes. THF, tetrahydrofolate; MTHFD1, methylenetetrahydrofolate 
dehydrogenase complex 1; SHMT, serine hydroxymethyltransferase; MTHF, 5,10-
methylenetetrahydrofolate; MTHFR, methylenetetrahydrofolate reductase; mTHF, 5-
methyltetrahydrofolate; Met, methionine; SAM, S-adenosylmethionine; MS, methionine 
synthase; MTs, methyltransferases; BHMT, betaine-homocysteine methyltransferase; SAH, 
S-adenosylhomocysteine; HCy, homocysteine; CBS, cystathionine-β-synthase; CGL, 
cystathionine-γ-lyase; CHDH, choline dehydrogenase; BADH, betaine aldehyde 
dehydrogenase; DMG, dimethylglycine; DMGDH, dimethylglycine dehydrogenase; SARDH, 
sarcosine dehydrogenase; GNMT, glycine-N-methyltransferase. 
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1.8.1 The methionine-homocysteine cycle and transsulfuration pathway 
A central methyl donor in one-carbon metabolism is S-Adenosylmethionine (SAM) which is 
derived from the amino acid methionine (50). Whenever SAM donates a methyl group it is 
converted to S-Adenosylhomocysteine (SAH) which in turn can be converted to 
homocysteine (51, 52). Homocysteine can further be remethylated back to methionine or go 
through the transsulfuration pathway to form cysteine. The remethylation of homocysteine 
back to methionine can happen in two ways and is reliant on the donation of a methyl group 
provided from metabolites related to either the choline oxidation pathway or the folate cycle. 
In the folate-dependent remethylation of homocysteine, 5-methyltetrahydrofolate (mTHF) 
function as the methyl donor in an enzymatic reaction catalyzed by methionine synthase (MS) 
where vitamin B12 serves as a cofactor (53). The other remethylation pathway uses betaine 
from the choline oxidation pathway as the methyl donor in a reaction catalyzed by betaine-
homocysteine methyltransferase (BHMT) (53). The transsulfuration pathway on the other 
hand leads to the irreversible removal of homocysteine through two vitamin B6-dependent 
enzymatic reactions that first leads to the formation of cystathionine and then to the formation 
of cysteine (54). 
 
1.8.2 The folate cycle  
Folate is a collective term that refers to the different coenzyme forms of vitamin B9 (55).  
Tetrahydrofolate (THF), a reduced form of folate, is the active form of the vitamin and 
function as a backbone in the folate cycle (55, 56). Naturally occurring folate in food is 
mainly present in the form of THF and dietary sources include dark green vegetables, liver 
and beans among others (57). The term folate also includes folic acid, which is a synthetic 
form of folate used in supplements and fortified foods as it is more stable and has higher 
bioavailability than natural folate (55, 58). However, folic acid is reduced to THF and further 
metabolized like the naturally occurring forms of the vitamin (56). Folate is mainly found in 
the circulation in the form of mTHF (57, 59).   
 
The folate cycle refers to the metabolism of folate inside our cells which provide the different 
coenzyme forms of folate. The first step in the folate cycle is the conversion of THF to 5,10-
methylenetetrahydrofolate (MTHF) which can occur in two ways. The one way is through a 
three-step reaction catalyzed by the enzyme methylenetetrahydrofolate dehydrogenase 
complex 1 (MTHFD1) which uses vitamin B3 as a cofactor (60, 61). The other way is 
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through the enzyme serine hydroxymethyltransferase (SHMT) which utilizes serine as the 
methyl donor and vitamin B6 as a cofactor leading to the formation of both MTHF and 
glycine (62). MTHF can further be metabolized with the help of methylenetetrahydrofolate 
reductase (MTHFR) which utilizes both vitamin B2 and B3 as cofactors to mTHF (63, 64). 
As mentioned, mTHF function as a methyl donor in the remethylation of homocysteine and 
this reaction yields THF which once again can go through the folate cycle.  
 
1.8.3 The choline oxidation pathway 
The choline oxidation pathway begins with the conversion of choline to betaine inside the 
mitochondrion (65, 66). This is catalyzed by two enzymatic reactions where the first is 
dependent on vitamin B2 and the second on vitamin B3 as cofactors (65, 66). Betaine can 
then diffuse into the cytosol to function as a methyl donor in the remethylation of 
homocysteine which in addition to methionine also yields dimethylglycine (DMG) (53). 
DMG can diffuse into the mitochondrion and be further demethylated to sarcosine in a 
vitamin B2-depedent enzymatic reaction (67). Sarcosine can further be demethylated to form 
glycine in another vitamin B2-dependent enzymatic reaction (67). From there glycine can 
either be demethylated to form serine in a vitamin B6-depedent reversible reaction catalyzed 
by SHMT or be converted back to sarcosine in the cytosol by the help of SAM as a methyl 
donor in a reaction catalyzed by glycine N-methyltransferase (GNMT) (68, 69).  
 
1.8.4 Markers of B-vitamin status  
 
Riboflavin, B2 
Riboflavin or vitamin B2, is a water-soluble vitamin which can be obtained from dietary 
sources such as meat, dairy and certain vegetables. In plasma, most of the riboflavin is found 
as free riboflavin whereas most of cellular riboflavin exist as either flavin mononucleotide 
(FMN) or flavin adenine dinucleotide (FAD) which are the active cofactor forms (70, 71). 
The function of riboflavin is mainly related to serving as cofactors for flavoproteins involved 
in redox reactions and energy metabolism among others (72). In one-carbon metabolism, 
riboflavin function as a cofactor for enzymes involved in both the transsulfuration pathway as 
well as the choline oxidation pathway (73, 74).  
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Niacin, B3  
Niacin is the collective term for nicotinamide (NAM), nicotinic acid (NA) and nicotinamide 
riboside, commonly referred to as vitamin B3 (75, 76). Niacin can be obtained in the diet 
through food sources such as meat, vegetables or cereals or through breakdown of the amino 
acid tryptophan (75). NAM and NA are both precursors of nicotinamide adenine dinucleotide 
(NAD) whose function is related to serving as a cofactor for enzymatic redox reactions and as 
an electron carrier in energy metabolism (75). As previously mentioned, several enzymatic 
reactions related to the folate cycle and choline oxidation pathway also depend on niacin in 
the form of NAD+ as cofactor. N1-methylnicotinamide (mNAM) is formed through the 
breakdown of NAD+ (77). Assessment of niacin status is often done by measuring the plasma 
concentration of NAM, NA and mNAM due to the fact that half-life of NAD in plasma is 
very short (75).  
 
Vitamin B6 
Vitamin B6 refers to a total of six compounds that are interconvertible, namely pyridoxal 
(PL), pyridoxine and pyridoxamine in addition to the phosphorylated forms of these 
compounds (78, 79). Dietary sources to vitamin B6 are animal sources such as meat and fish, 
but also whole grains. Vitamin B6 serves as a cofactor for multiple enzymatic reactions and 
pyridoxal-5-phosphate (PLP) is the active cofactor variant of the vitamin (78, 79). PL, 
pyridoxine and pyridoxamine can be converted to the active cofactor PLP through the action 
of different enzymes (78, 79). As mentioned, both the enzymatic reactions in the 
transsulfuration pathway are dependent on vitamin B6 in the form of PLP as a cofactor in 
addition to the enzyme SHMT which is responsible for the interconversion of glycine and 
serine (79). Vitamin B6 exists mostly in the form of PLP in blood, however some of it is also 
found in the form of PL and 4-pyridoxic acid (PA) (79, 80). Assessment of vitamin B6 status 
is often done by measuring the concentration of PLP in plasma, however measurement of the 
total circulating forms of vitamin B6 has been suggested to be more accurate as plasma PLP 
can be influenced by factors such as smoking or inflammation (79, 80).  
 
Cobalamin, B12 
Cobalamin, also known as vitamin B12, is the last of the B-vitamins that will be discussed in 
this thesis. Dietary sources to cobalamin include meat, fish and dairy as well as many other 
foods of animal origin (81). In the body, cobalamins function is to serve as a cofactor both for 
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MS responsible for the remethylation of homocysteine and for metylmalonyl-CoA mutase 
which catalyzes the breakdown of methylmalonyl-CoA to succinyl-CoA (81, 82). In the case 
of cobalamin deficiency, both of these enzymes will be inhibited. This in turn will lead to an 
accumulation of homocysteine in addition to methylmalonic acid (MMA) which is formed in 
a non-enzymatic reaction from methylmalonyl-CoA (81, 82). Several markers of vitamin B12 
exist including total serum cobalamin, total homocysteine and MMA. Nevertheless, none of 
them have been shown to be superior when utilized separately due to their limitations. For 
example, in blood most of the cobalamin is bound to haptocorrin and a less amount is bound 
to holo-transcobalamin (holo-TC) (81-83). The cells however are only able to take up holo-
TC and thus measuring total serum cobalamin might not be the best method to assess vitamin 
B12 status (81, 82). Measurement of total homocysteine as an indicator of vitamin B12 status 
also have its flaws as homocysteine is dependent on folate and cobalamin to be remethylated 
(82). Measurement of MMA can be used as an indicator of cobalamin deficiency, although 
MMA levels may be influenced by factors such as reduced renal function and older age (82, 
84).  
 
1.8.5 One-carbon metabolism, overweight and diet 
Some of the metabolites discussed have been found to be altered with obesity. Specifically, 
increased total plasma concentrations of cysteine have been linked to both increased fat mass, 
obesity and BMI in men and women (85-88). Additionally, lower circulating concentrations of 
glycine has also been associated with obesity (89). Several studies have also shown that diet 
influences the circulating concentrations of one-carbon metabolites. For example, one study 
investigated the effect of a 7-day restriction of the dietary intake of methionine and cysteine 
while supplementing with polyunsaturated fatty acids (PUFA) and reported reduced plasma 
concentrations of methionine and cystathionine and increased plasma concentrations of total 
homocysteine and serine (90, 91). Another study investigated the postprandial effects of a meal 
low in cysteine and methionine with PUFA-enrichments and reported reduced plasma 
concentrations of total cysteine (92). Furthermore, in another study, higher concentrations of 
glycine, serine, cystathionine and riboflavin and lower concentrations of cysteine and 
cobalamin was observed when replacing approximately 6.5 E% from saturated fatty acids with 
PUFA (93).  
 
1.9 PPAR-α and personalized nutrition  
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1.9.1 The relevance of PPARα in relation to nutrition 
Peroxisome proliferator-activated receptor α (PPARα) is a nuclear receptor of particular 
interest in relation to nutrition as it regulates the metabolism of lipids, carbohydrates and 
amino acids, making PPARα a central factor in energy metabolism (94). Upon activation, 
either by fatty acids supplied by the diet or produced in the liver in response to a fasting state, 
PPARα function through upregulating genes that are responsible for β-oxidation. PPARα is 
consequently profusely expressed in the liver, heart, brown adipose tissue and skeletal muscle 
which are all tissues with high rates of fat oxidation (95-98). PPARα is not only relevant in 
the metabolism of lipids, but also has important functions in the metabolism of carbohydrates 
and amino acids. In cases of sparse glucose availability such as fasting, PPARα will 
upregulate genes which facilitate gluconeogenesis and consequently downregulate genes that 
facilitate the storage of glucose in order to ensure stable supply of glucose to the brain and 
other glucose-dependent tissues (98). Furthermore, PPARα suppress the degradation of amino 
acids through downregulating the expression of enzymes involved in the catabolism of amino 
acids (99).  
 
The activation of PPARα can be linked to diet as it supplies fatty acids which act as 
activators, and especially the long-chained polyunsaturated fatty acids (PUFA’s) and related 
compounds (100). Furthermore, this might imply that the level of dietary activation of PPARα 
may be influenced by both the amount and composition of fatty acids supplied through the 
diet (96). Given that both a fasting state and dietary intake of fatty acids activate PPARα, a 
ketogenic diet is of interest as it consists of a high intake of fats and a low intake of 
carbohydrates and thereby imitate a fasting state by inducing the use of fats as primary fuel.  
 
1.9.2 Biomarkers of PPARα-activation  
Animal studies have shown that activation of PPARα through the administration of PPARα-
agonists leads to altered blood concentration of metabolites related to one-carbon metabolism, 
the choline oxidation pathway and markers of vitamin B status (101, 102). In both of these 
studies, activation of PPARα lead to marked increases in the plasma concentration of DMG, 
glycine, serine, NAM, mNAM, PLP, PL and MMA and a reduction in the plasma 
concentration of riboflavin. Few studies have investigated the effect of PPARα-activation on 
plasma concentration of metabolites related to one-carbon metabolism in humans, however 
treatment of humans with fibrates which are PPARα-agonists have been associated with 
increased plasma concentrations of homocysteine and decreased plasma concentrations of 
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betaine (103, 104). The findings that the concentration of several metabolites such as those 
mentioned above are altered with activation of PPARα, suggest that these metabolites 
potentially can function as biomarkers of PPARα-activity. Furthermore, this may have clinical 
importance with regards to personalized nutrition advice as PPARα is an important regulator 
of energy metabolism and specifically increases the metabolism of fat upon activation. Given 
the important role of PPARα in the regulation of energy metabolism, dietary response may 
differ in individuals with high or low endogenous PPARα-activity, respectively. This is of 
particular interest when considering diets with different carbohydrate and fat content.  
Hypothesis and aims 
When considering weight loss, there is a substantial inter-individual variation in the response 
to different diets. Identifying biological factors which may predict who will respond to a 
given diet has the potential to improve our understanding and treatment of overweight and 
obesity. Endogenous PPARα-activity may be a key factor influencing the response to diets 
differing in fat content. The aim of this study was therefore to determine whether baseline 
plasma concentrations of metabolites related to one-carbon metabolism and B-vitamin status, 
of which some have been suggested as potential biomarkers of PPARα-activity, was 
associated with weight loss and moreover could predict inter-individual differences in the 
weight loss response to two diets with very different fat- and carbohydrate content. We 
further hypothesized that the metabolites suggested to reflect endogenous PPARα-activity 






2.1  Study design 
This master project is a sub-study based on data obtained from a randomized controlled trial 
(FATFUNC, ClinicalTrials.gov, Identifier NCT01750021) investigating the effects of two 
diets differing in fat and carbohydrate content on total body weight, visceral fat mass, 
abdominal subcutaneous fat mass and waist circumference and other parameters of metabolic 
importance in obese men (105). The original study was carried out in Bergen, Norway from 
January to May 2013. The recruitment of participants was done through a post in the local 
newspaper with a description of the project. The inclusion and exclusion criteria for the study 




• Age between 30-50 years  
• Abdominal obesity 
• Normal fasting blood glucose < 7 mmol/L 
• Waist circumference > 98 cm 
• BMI > 29 or percentage body fat ≥ 25  
Exclusion criteria: 
• Severe diseases including inflammatory bowel diseases or known food allergies  
• Regular medication except alkalizing gastric buffers  
• Attempts at systematic weight reduction over the previous 6 months  
• Regularly consuming > 2 alcohol units per week  
Two pre-screenings were performed to secure that all participants met inclusion criteria by the 
start of the intervention. Six men did not meet inclusion criteria after pre-screening and 
additionally four recruited participants withdrew before randomisation. During the study 
period of 12 weeks, the participants came in for study visits at baseline, 4, 8 and 12 weeks.  
 
2.2 Diets 
46 participants were randomly allocated to either following a low-fat, high-carbohydrate diet 
(LFHC) or a very-high fat, low-carbohydrate diet (VHFLC). The LFHC-diet consisted of 
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30% of total energy intake from fat and 53 % of total energy intake from carbohydrates 
whereas the VHFLC-diet consisted of 73% of energy from fat and 10% energy from 
carbohydrates. Both the LFHC- and the VHFLC-diet were similar in terms of protein (17 E 
%) and energy content (∼2090 kcal). Information on their diet group allocation was disclosed 
to each participant after baseline measurements and samples were taken. 
 
Participants were provided with a recipe booklet consisting of more than hundred pre-
specified meals each of which was designed to have the exact macronutrient profile of the 
respective diets. The recipes included minimal amounts of highly processed foods and added 
sugar. Participants were also asked to take a vitamin and mineral supplement without iron 
(Solaray Spektro) for 8 weeks before the start of the intervention to limit individual 
differences in macronutrient status that might influence energy metabolism. More detailed 
descriptions of the intervention as well as the composition of the diets have been previously 
published (105).  
 
2.3 Body weight measurements  
Measurements of body weight were performed at each study visit. Body weight 
measurements of the participants were taken while barefoot and in light clothing by using 
InBody 720; Biospace which is a segmental multifrequency bioelectrical impedance 
measurement system. Participants were also asked to use the restroom and to stand in an 
upright position for over 5 minutes prior to the measurements.  
 
2.4 Blood samples and quantification of metabolites  
Blood samples of venous blood including whole blood, plasma and serum was collected from 
the participants during fasting conditions (overnight or for ≥10 hours) at every study visit. 
Following preparation, the blood samples were stored at -80°C. For this sub-study, the 
metabolites of interest were one-carbon metabolites related to the methionine-homocysteine 
cycle, transsulfuration pathway, choline oxidation pathway and markers of B-vitamin status. 
Both the analysis of one-carbon metabolites as well as B-vitamins were performed at Bevital 
A/S, Bergen, Norway (http://bevital.no/), where sample handling was carried out by robotic 
workstations. Quantification of the metabolites was performed using gas- or liquid 
chromatography coupled to tandem mass spectrometry (GC-MS/MS, LC-MS/MS) (106-108) 
or microbiological assays (109). An overview of the metabolites and the type of 




Table 1. Analytical methods and plasma metabolites 
Analytical method 
Plasma 
metabolites Normal range 1 ICC 
  Methionine 18-50 μmol/L 0.33 
  Homocysteine <15 μmol/L  0.72 
  Cysteine 150-350 μmol/L 0.62 
GC-MS/MS  Glycine 150-300 μmol/L 0.81 
  Serine 95-125 μmol/L 0.71 
  MMA <0.26 μmol/L 0.81 
  Sarcosine 0.7-2.3 μmol/L 0.68 
    Cystathionine <0.4 μmol/L 0.63 
  Choline 5-15 μmol/L 0.36 
  Betaine 20-60 μmol/L 0.65 
  DMG 1.5-5 μmol/L 0.64 
  PLP 15-150 nmol/L 0.70 
  PL 5-150 nmol/L 0.62 
LC-MS/MS  PA 10-200 nmol/L 0.58 
  Riboflavin 5-100 nmol/L 0.79 
  FMN 3-30 nmol/L  0.69 
  NAM 100-600 nmol/L NA 
  mNAM 20-250 nmol/L NA 
    Folate (mTHF) >7.5 nmol/L   0.56  
Microbiological assay Cobalamin >150 pmol/L 0.82 
 
ICC indicates intraclass correlation coefficient; DMG, dimethylglycine; FMN, flavin 
mononucleotide; NAM, nicotinamide; mNAM, N1-methylnicotinamide; PLP, pyridoxal-5’-
phospate; PL, pyridoxal; PA, pyridoxic acid; MMA, methylmalonic acid; NA, not available. 
1 Normal range values retrieved from bevital.no  
 
 
Metabolite concentrations are not static and varies during both short- and long-term. The 
intraclass correlation coefficient (ICC) is a descriptive statistic quantifying the between-
subject variation relative to the total variation and is frequently reported as a measure of 
within-person reproducibility. ICC lies within 0-1, where higher values indicate better within-
person reproducibility (a higher proportion of the variation is between-subjects) and represent 
the extent to which a single measurement reflects long-term average exposure within a 
person. The conventional cutoffs are <0.4 which is considered to be reflect poor 
reproducibility and values >0.75 is considered to reflect excellent reproducibility. The ICC of 
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the metabolites included in this thesis are generally reflecting good to excellent 
reproducibility.  
 
2.5 Statistical analyses and presentation of data 
The data was explored according to the diet groups. Baseline characteristics and baseline 
plasma concentration of metabolites are presented as means (standard deviations; SD) or 
counts (%) for each group and for the total population. In addition, body weight and BMI at 4, 
8 and 12 weeks are also presented as means (SD). The overall association between baseline 
plasma metabolite concentrations and subsequent weight loss were assessed by calculating 
spearman correlations with weight change in % at 12 weeks. Inverse correlations indicate that 
increasing metabolite concentration was associated with larger weight loss. To visualize the 
association between baseline metabolite concentration and weight loss, weight loss in % from 
baseline to 12 weeks was plotted against the metabolite concentrations at baseline. The 
individuals were coloured according to diet group, and linear regression lines extrapolated to 
the range of the metabolites were superimposed on the plot to visualize trends within the diet 
groups. To formally test the potential interaction between the baseline metabolite 
concentrations and the diets, an interaction term was added to a linear regression analysis 
comparing body weight at week 12, adjusted for baseline body weight. For the purpose of 
data visualization in order to look for trends, the following extreme data points, outside the 
normal range, were omitted from the plots: 59.03 for methionine µmol/L, 1.0 µmol/L for 
cystathionine, 9.88 µmol/L for DMG and 48.29 nmol/L for FMN. All data were however 
included in the linear regression analyses to formally evaluate the potential interaction. 
Spearman correlations between all metabolites at baseline, as well as markers of glycaemic 
status previously used to predict response to diets differing in fat and carbohydrate content, 
are presented in a correlation matrix.  
 
The statistical analyses were performed with R version 4.0.3 (2020-10-10) for Mac, and the 
following packages within the tidyverse; ggplot, broom, corrr and rmarkdown. Microsoft 
Excel version 16.44 (20121301) was also used for organization of the tables. Inkscape was 
the software used to make vector graphics. 
 
2.6 Ethics statement  
The study was approved by the Regional Ethics Committee (2011/2282/REK west) and 
conducted according to the criteria set by the Declaration of Helsinki. All participants gave 
 29 
written informed consent. The dataset provided for data analysis were anonymized to secure 
that no participants could be identified.   
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3 Results  
 
3.1 Baseline characteristics  
Of the 46 participants randomized to follow either the LFHC- or VHFLC-diet, only 38 men 
were included in the data analysis. Eight participants were excluded, whereof two participants 
withdrew before baseline visits and four dropped out early during follow-up. Additionally, 
two participants from the VHFLC-group were excluded due to lacking compliance on diet 
records and data collected at study visits. The data analysis thus consisted of 18 participants 
in the LFHC-group and 20 in the VHFLC-group.  
 
Table 2 provides baseline characteristics for the LFHC- and VHFLC-group and for the total 
population. The mean age was equal in the two groups at 40.2 years. There were twelve 
smokers in the total population, corresponding to six smokers in the LFHC-group (33.3 %) 
and six smokers in the VHFLC-group (30.0 %). Both diet groups had a similar reduction in 
body weight in total and at the different time points from baseline to week 12 where the mean 
weight loss were 12.2 kg (11.0 %) in the LFHC-group and 12.0 kg (10.5 %) in the VHFLC-
group, respectively. Similarly, BMI decreased by 3.7 points in the LFHC-group compared to 
3.5 points in the VHFLC-group during the study period.  
 
Baseline characteristics of the metabolites are also presented in Table 2 for both diet groups 
and for the total study population. In the methionine-homocysteine cycle and transsulfuration 
pathway, the baseline mean concentration of methionine and cysteine were slightly higher in 
the LFHC-group whereas the baseline mean concentration of homocysteine and cystathionine 
were slightly higher in the VHFLC-group. For the metabolites related to the choline oxidation 
pathway, the baseline mean concentration of choline, betaine, sarcosine, glycine, and serine 
were all slightly higher in the LFHC-group whereas the baseline mean concentration of DMG 
were marginally higher in the VHFLC-group. The baseline mean concentration of sarcosine 
were also slightly above normal range in both diet groups and in the total population.  
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Table 2. Baseline characteristics of the study population  
Variable   Total population LFHC VHFLC   r 1 
Age (years)  40.2 (5.00)  40.2 (4.50) 40.2 (5.53)  
Smoking2   12 (31.5 %)  6 (33.3 %) 6 (30.0 %)  
Body weight (kg)           
Week 0  112 (11.6)  111 (13.8) 114 (9.47)  
Week 4  106 (11.0)  104 (13.0) 107 (9.03)  
Week 8  103 (10.5)  101 (12.5) 104 (8.36)  
Week 12  100 (9.90)  98.8 (11.8) 102 (7.93)  
BMI (kg/m2)            
Week 0  33.9 (2.99)  33.6 (3.62) 34.1 (2.35)  
Week 4  31.9 (2.87)  31.5 (3.50) 32.2 (2.21)  
Week 8  31.0 (2.78)  30.7 (3.39) 31.3 (2.13)  
Week 12  30.3 (2.64)  29.9 (3.29) 30.6 (1.90)  
Metabolites             
One-carbon metabolites, μmol/L        
Methionine  28.0 (6.62)  28.7 (4.33) 27.4 (8.23) - 0.15 
Homocysteine 9.89 (1.99)  9.82 (2.09) 9.96 (1.95)   0.08 
Cystathionine 0.22 (0.14)  0.20 (0.048) 0.23 (0.20)   0.04 
Cysteine  320 (31.8)  326 (36.1) 315 (27.2)   0.06 
Choline oxidation pathway metabolites, μmol/L    
Choline  10.1 (1.57)  10.3 (1.76) 9.86 (1.40)   0.17 
Betaine  34.3 (6.57)  35.0 (6.45) 33.7 (6.78) - 0.18 
DMG  4.13 (1.23)  4.06 (0.76) 4.20 (1.56)   0.22 
Sarcosine  2.81 (0.46)  2.89 (0.45) 2.73 (0.47)   0.11 
Glycine  201 (31.3)  211 (28.1) 192 (31.9)   0.10 
Serine  105 (16.7)  107 (18.9) 102 (14.7) - 0.07 
Markers of B-vitamin status     
B2 vitamers, nmol/L      
Riboflavin  32.6 (20.0)  37.2 (24.8) 28.4 (13.9) - 0.10 
FMN  18.2 (7.78)  19.7 (9.31) 16.9 (6.02) - 0.20 
       
B3 vitamers, nmol/L      
NAM  791 (172)  821 (176) 764 (168)   0.10 
mNAM  200 (72.4)  202 (56.6) 198 (85.7)   0.21 
       
B6 vitamers, nmol/L      
PLP  109 (56.0)  113 (61.3) 105 (52.2)   0.00 
PL  26.1 (19.1)  30.5 (24.1) 22.1 (12.3) - 0.15   
PA  66.5 (55.8)  80.0 (70.1) 54.3 (36.6) - 0.12 
       
Folate, nmol/L 15.3 (6.75)  15.5 (4.77) 15.1 (8.26)   0.06 
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Cobalamin, pmol/L 527 (121)  566 (136) 496 (99.4)   0.23 
MMA, μmol/L 0.14 (0.049)  0.14 (0.054) 0.14 (0.045)   0.12 
All variables are presented as mean (SD) except smoking which is presented as counts (%). 
DMG indicates dimethylglycine; FMN, flavin mononucleotide; NAM, nicotinamide; mNAM, 
N1-methylnicotinamide; PLP, pyridoxal-5’-phospate; PL, pyridoxal; PA, pyridoxic acid; 
MMA, methylmalonic acid; LFHC, low-fat, high-carbohydrate diet; VHFLC, very high-fat, 
low-carbohydrate diet.  
1 Spearman´s Rank correlation coefficient of the relationship between weight loss and 
baseline metabolite concentrations. Inverse correlations indicate that increasing metabolite 
concentration was associated with larger weight loss.  
2Smoking is calculated from plasma cotinine > 85 nmol/L. 
 
Concerning the B-vitamins, we observed slightly higher baseline mean concentrations of the 
B2 vitamers riboflavin and FMN in addition to the B3 vitamers NAM and mNAM in the 
LFHC-group compared to the VHFLC-group (Table 2). The baseline mean concentration of 
NAM were also slightly above normal range in both diet groups and in the total population 
(Table 2). The baseline mean concentration of the B6 vitamers PLP, PL and PA were also 
somewhat higher in the LFHC-group compared to the VHFLC-group (Table 2). No between-
group differences in baseline mean concentration of folate and MMA was observed, however 
baseline mean concentration of cobalamin were slightly higher in the LFHC-group compared 
to the VHFLC-group (Table 2). Although some between-group differences in the baseline 
concentration of the different metabolites were observed, the between-group differences were 
generally small, as expected in a randomized study.  
 
The Spearman’s rank correlation coefficient of the association between the different 
metabolites at baseline and weight change demonstrated that baseline concentrations of 
homocysteine, cystathionine, cysteine, choline, DMG, sarcosine, glycine, NAM, mNAM, 
folate, cobalamin and MMA were positively associated with weight change indicating that 
lower concentrations were associated with more weight loss (Table 2). The opposite was 
observed for methionine, betaine, serine, riboflavin, FMN, PL and PA where higher 
concentrations were associated with more weight loss. However, all the correlation 
coefficients were close to zero and thus no strong associations were observed (Table 2).  
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Figure 3 shows the Spearman correlation between all the metabolites as well as markers of 
glycemic status. The markers of glycemic status were glucose, HbA1c, homeostatic model 
assessment of insulin resistance (HOMA1-IR) and insulin. The metabolites that were most 
strongly positively correlated with the markers of glycemic status were DMG and 
cystathionine. The metabolite with the strongest negative correlation with the markers of 
glycemic status was mNAM. Glycine was also negatively correlated with all the markers of 
glycemic status with the exception of glucose.  
 
Figure 2. Spearman correlation matrix of the correlation between baseline values of all 
one-carbon metabolites as well as markers of glycemic status.   
Values close to 1 indicate a strong positive relationship; an increase in one variable also leads 
to an increase in the other variable. Values close to -1 indicate a strong negative relationship 
as the value of one variable increase the value of the other variable decrease. DMG indicates 
dimethylglycine; FMN, flavin mononucleotide; NAM, nicotinamide; mNAM, N1-
methylnicotinamide; PLP, pyridoxal-5’-phospate; PL, pyridoxal; PA, pyridoxic acid; MMA, 




3.2 Plasma concentration of metabolites and weight loss response to diets  
 
3.2.1 Metabolites of the methionine-homocysteine cycle and transsulfuration 
pathway 
Figure 3 illustrates the observed relationship between baseline metabolite concentrations and 
weight loss response (%) following the LFHC- and VHFLC-diet. For metabolites related to 
the methionine-homocysteine cycle and transsulfuration pathway the most notable finding 
was for homocysteine. The LFHC-diet trended towards being most effective for weight loss 
for lower baseline concentrations of homocysteine whereas the VHFLC-diet trended towards 
being more effective when homocysteine was higher. For cystathionine, between group 
differences in weight loss response were small for lower concentrations, however the LFHC-
diet appeared to be more effective compared to the VHFLC-diet with increasing 
concentrations, although this observation appeared to be heavily influenced by a few 
individual observations. For methionine and cysteine, no specific trends were observed.  
 
3.2.2 Choline oxidation pathway metabolites 
Some interesting trends were also observed when analyzing the metabolites in the choline 
oxidation pathway (Figure 3). For choline, low baseline concentrations were observed to be 
associated with a larger weight loss compared to higher concentrations irrespective of diet 
type which was also indicated by the correlation in Table 2. Furthermore, between group 
differences in weight loss response for different concentrations of choline were small. 
Between group differences in weight loss response for lower concentrations of betaine were 
small, but the LFHC-diet trended towards being more effective for higher concentrations of 
betaine. Regarding DMG, low baseline concentrations were associated with the highest 
weight loss response irrespective of diet type. Nonetheless, the LFHC-diet were more 
effective compared to the VHFLC-diet when DMG concentrations were higher. Concerning 
sarcosine, the LFHC-diet trended to be more effective for lower concentrations whereas the 
VHFLC-diet trended to be more effective for higher concentrations. The opposite pattern was 
seen for glycine, where the VHFLC-diet seemed to be more effective for lower concentrations 
while the LFHC-diet slightly outperformed the VHFLC-diet when glycine concentrations 
were higher. Regarding serine, higher concentrations tended to be associated with a slightly 
higher weight loss irrespective of diet type, but not specific differences were observed 
between the diet groups.        
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Figure 3. Results on metabolite concentrations and weight loss (%) following the LFHC- and VHFLC-diet.   
P-int indicates the P-values of interaction between baseline metabolite concentrations and diet type. DMG indicates dimethylglycine; FMN, 




3.2.3 Markers of B-vitamin status 
Some trends were also observed when analyzing the markers of B-vitamin status (Figure 3). 
The observed trends for the B2 vitamers riboflavin and FMN were modest. For riboflavin, the 
LFHC-diet tended to be slightly more effective when concentrations were in the lower range, 
whereas the VHFLC-diet tended to be a bit more effective for higher concentrations, however 
between-group differences were small. No clear trend was observed between diet type and 
metabolite concentrations for FMN, but higher concentrations tended to result in a slightly 
larger weight loss compared to lower concentrations irrespective of diet type. No clear trends 
were observed for the B3 vitamer NAM. Regarding mNAM, the LFHC-diet trended to be the 
most effective for weight loss the lower the concentrations. The VHFLC-diet on the other 
hand, were equally effective regardless of mNAM concentration, but outperformed the 
LFHC-diet when initial mNAM concentrations were higher. The B6 vitamers PL, PLP and 
PA all showed similar trends. The LFHC-diet tended to be more effective for weight loss the 
lower the concentration of these metabolites, whereas the VHFLC-diet were more effective 
when concentrations were higher, albeit there were few participants with high concentrations 
of PL and PA.  
 
Concerning folate, the VHFLC-diet showed an equal weight loss response for all baseline 
concentration values. The LFHC-diet on the other hand trended towards being most effective 
for lower baseline concentrations and less effective for higher concentrations. No clear trend 
was observed between diet type and metabolite concentration of cobalamin, but lower 
concentrations seemed to be associated with a slightly larger weight loss response compared 
to higher concentrations irrespective of diet type. Concerning MMA, the LFHC-diet tended to 
be more effective for lower concentrations compared to the VHFLC-diet. The VHFLC-diet 
however was observed to be more effective the higher the concentrations, however there were 
few participants with high MMA concentrations.  
 
To summarize, some differences in the response to the diets in terms of weight loss, were 
observed according to the baseline plasma concentration of the metabolites. Notably, the 
LFHC-diet outperformed the VHFLC-diet for lower baseline concentrations of homocysteine, 
sarcosine, mNAM, PL, PLP, PA and MMA and for higher concentrations of cystathionine, 
betaine, DMG, glycine and folate (Figure 3). The VHFLC-diet produced the superior result 
when concentrations of glycine were lower and for higher concentrations of homocysteine, 
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sarcosine, mNAM, PL, PLP, PA and MMA (Figure 3). Despite observing between-group 
differences in weight loss response for high- and low baseline concentrations of several 
metabolites, the formal tests for interaction between metabolite concentrations and diet type 
were inconclusive and indicated that the data did not provide good evidence against the null 




4.1 Methodological strengths and limitations  
In this study among obese men, we studied whether metabolites related to one-carbon 
metabolism, the choline oxidation pathway and markers of B-vitamin status were associated 
with weight loss and whether they could predict inter-individual differences in the weight loss 
response to a low-fat, high-carbohydrate diet and a very high-fat, low carbohydrate diet. 
However, the results of the current study should be interpreted in light of some strengths and 
limitations which will be discussed in the following sections.  
 
4.1.1 Strengths   
One strength of the study is the relatively long duration of the dietary intervention. Previous 
studies have suggested that it may take between three to six weeks for the body to 
metabolically adapt from utilizing carbohydrates to fat as the primary energy source (110, 
111). Considering that the dietary intervention in the current study lasted for 12 weeks, it is 
less likely that our results may have been influenced by lack of metabolic adaptation to the 
VHFLC-diet. On the other hand, a 12-week follow-up is insufficient in terms of investigating 
whether measuring metabolite concentrations can predict the most effective diet for weight 
loss in the long term, that is beyond 12 weeks. 
 
Adherence to the prescribed diets is generally a challenge in dietary intervention studies. 
However, in this study the participants were closely monitored, as they were asked to record 
their dietary intake throughout the study, using an online food record system (105). Food 
records are considered a reactive dietary instrument, meaning that their use influences 
behavior, i.e., people change their diet when recording. It is established that people alter their 
eating behavior when being monitored (112). Therefore, the use of food records likely 
contributed to increased adherence to the assigned diets as the participants to a greater extent 
were reminded to follow the diets they were assigned to. To further verify adherence to the 
diets in the current study, respiratory exchange ratio (RER) was calculated which can be used 
as an indicator of whether carbohydrates or fat is the primary source of energy supply to the 
body (105). The RER demonstrated that the intake of fat increased substantially in the 
VHFLC-group which further supports that the participants adhered to the assigned diets.  
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Another strength of the study is the randomized controlled design which contributes to 
minimize potential bias and confounding factors in either one of the diet groups influencing 
the results as well as making the groups comparable. When done properly, any potential 
differences between the groups should after randomization thus be due to chance. In the 
current study we observed that the average baseline concentration of the metabolites as well 
as mean age and baseline body weight were relatively similar between the two diet groups 
which points to a successful randomization of the participants. Furthermore, the participants 
included in the study were relatively homogenous in terms of all being male, middle-aged and 
having no severe diseases or diabetes which could have impacted the results in terms of 
increasing the inter-individual variability in response to the diets. On the other hand, studying 
such a homogenous group of men may reduce the external validity of the study and thus limit 
our ability to extrapolate our findings outside the study population. Indeed, some argue that 
one should not necessarily strive for representative samples to improve generalization as 
population representative samples might reduce internal validity by increasing variability 
(113). Increased variability in a study sample further makes it more difficult to detect any 
potential effect of a given intervention.  
 
An additional strength of the study is the fact that the blood samples of the participants were 
taken in a fasting state, preventing a large influence from recent dietary intake on biomarker 
concentrations. Further, the activity of PPARα is induced in the fasting state and any 
individual differences in endogenous PPARα-activity, as measured through the suggested 
biomarkers, should therefore be better reflected in the fasting state as opposed to if the 
measurements were taken in the fed state. However, some factors might have contributed to 
some of the metabolites being less reflective of endogenous PPARα-activity and thus also 
impacted the usefulness of these as reliable predictors of weight loss response. For example, 
the participants were asked to take a supplement which contained riboflavin, niacin, 
pyridoxine, folate and cobalamin (Solaray Spektro) for 8 weeks before the start of the 
intervention. Considering that we use vitamers of these B-vitamins as biomarkers of 
endogenous PPARα-activity, the use of this supplement might have led to bias in terms of not 
being representative of PPARα-activity, but rather a measure of adherence to the use of the 
supplement. Nevertheless, participants in both groups were asked to take the vitamin- and 
mineral supplement so it should not contribute to differences between the groups. The second 
factor which might have impacted the usefulness of the metabolites as predictors of weight 
loss response to the diets is the inclusion of smokers as smoking has been shown to influence 
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several metabolites related to one-carbon metabolism and thus may also have influenced the 
metabolites used in this study as predictors of weight loss response (78, 114). However, as the 
number of smokers were equal in both diet groups, this is not expected to contribute to 
between-group differences albeit it does not exclude the possibility of influence due to the 
potential differences in smoking intensity. 
 
The outcome measure of interest in this study was weight loss. Weight loss can be expressed 
both in absolute and relative terms. When visualizing the association between baseline 
metabolite concentration and weight loss in Figure 3, we chose to report weight change from 
baseline to the end of the intervention in % as opposed to absolute weight change. This can be 
considered a strength as % weight change often is the preferred outcome measure in clinical 
settings, but also because absolute weight change is more affected by differences in baseline 
body weight. Using % weight change can therefore be a way of standardizing this. Further, 
absolute weight change can also be expected to be larger among those with higher initial body 
weight, partly due to regression of the mean. Thus, absolute weight change is not directly 
comparable between individuals unless baseline body weights between the individuals are 
similar. In the formal tests for interactions between the baseline metabolite concentrations and 
the diet groups, we compared the body weight at the end of the intervention adjusted for 
baseline body weight. This is the recommended method when evaluating between-group 
differences in continuous outcome measures (115).  
 
Some strengths should be mentioned related to the exposure metabolites. Biomarker 
quantification were performed by trained personnel at Bevital A/S, using established 
automated methods based on mass spectrometry. In general, the ICC of the metabolites are 
considered good to excellent, limiting the possibility of misclassification when ranking the 
participants according to metabolite concentration. Further, we used a targeted metabolomics 
approach, focusing on the metabolic pathways related to one-carbon metabolism, as well as 
markers of B-vitamin status, and all results are transparently reported regardless of outcome.  
 
4.1.2 Limitations 
Given the exploratory nature of this study, we chose to primarily analyse the data graphically 
as the main objective was to look for overall trends. However, we did conduct a formal test 
for the interaction between the diets and the baseline metabolite concentrations. For a long 
time, an important aspect of scientific research has been null-hypothesis testing where 
 41 
observations are considered to be statistically significant if the p-value is below a certain 
threshold which is often set to be p=0.05. Consequently, if the p-value is >0.05, the 
observations are considered to be statistically insignificant. However, this dichotomous way 
of deeming observations to be significant or not has garnered much criticism over the past 
years as it is often misinterpreted and moreover may contribute to wrong interpretations of 
results (116-118), as well as selective reporting contributing to publication bias, 
overestimation of effect sizes and the replication crisis (119). Additionally, the p-value does 
not measure how large or important an observed effect is (117, 118). Essentially, the p-values 
obtained from the tests for interactions herein represents the likelihood of obtaining the 
current results if in reality no such interactions exist, and the p-value is thus a continuous 
measure of the compatibility of our data with the entire model of interaction along with all the 
background assumptions (120). Importantly, the p-value is also subject to being affected by 
sample size as its calculation is based on variance. In general, the larger the sample size the 
less variation and conversely, the smaller the sample size the larger variation (121). Thus, 
small sample sizes provide poor statistical power to detect an interaction and consequently 
increases the likelihood of not detecting a real effect which is often referred to as a false 
negative. In addition, it has been pointed out that much larger samples sizes are needed to 
estimate an interaction compared to estimating a main effect (121). Considering the small 
sample size and consequently the low power in this study, it is therefore likely that we were 
unable to discover any potential real effects.  
 
The small sample size also contributed to a few high observations having a relatively large 
impact on the trend lines for several of the metabolites in Figure 3. Although an attempt was 
made to remove some of the most extreme observations outside normal range for 
cystathionine, DMG, methionine and FMN, there were also generally few individuals with 
concentrations in the higher range of cystathionine, PL, PA, folate and MMA and most 
individuals had concentrations in the lower range (Figure 3). This might thus have contributed 
to false or misleading trends especially for high concentrations of these metabolites. A larger 
sample size might have been able to reduce the impact of the few high observations and 




4.2 Discussion of the results 
The primary aim of this study was to determine whether baseline plasma concentrations of 
metabolites related to one-carbon metabolism and B-vitamin status, of which some have been 
suggested as potential biomarkers of PPARα-activity, was associated with weight loss and 
moreover could predict inter-individual differences in the weight loss response to two diets 
with very different fat- and carbohydrate content. We further hypothesized that the 
metabolites suggested to reflect endogenous PPARα-activity would be similarly associated 
with weight loss response to the diets. 
 
We did not observe strong associations between baseline plasma metabolite concentrations 
and weight loss (Table 2). However, we did observe some differential trends in weight loss 
response according to baseline plasma metabolite concentrations and diet type (Figure 3). 
Specifically, we observed that the LFHC-diet outperformed the VHFLC-diet for lower 
baseline concentrations of homocysteine, sarcosine, mNAM, PL, PLP, PA and MMA and for 
higher concentrations of cystathionine, betaine, DMG, glycine and folate (Figure 3). The 
VHFLC-diet on the other hand was observed to produce the superior result when 
concentrations of glycine were low and for higher concentrations of homocysteine, sarcosine, 
mNAM, PL, PLP, PA and MMA (Figure 3). However, due to small sample size, the formal 
tests for interaction between metabolite concentrations and diet type were inconclusive. No 
specific trends in terms of weight loss response according to diet type were observed for 
baseline concentrations of methionine, cysteine, choline, serine, riboflavin, FMN, NAM and 
cobalamin (Figure 3). 
 
4.2.1 PPARα-activity and weight loss response to the diets  
Considering the important role of PPARα in energy metabolism, we hypothesized that the 
metabolites previously suggested to reflect PPARα-activity, as demonstrated in animal studies 
(101, 102), would be similarly associated with weight loss response to the diets. For higher 
concentrations of some of the metabolites suggested to reflect PPARα-activity, namely 
mNAM, PL, PLP, and MMA, we observed that the VHFLC-diet appeared most effective 
(Figure 3). However, for higher concentrations of DMG and glycine, the opposite was 
observed (Figure 3). On the other hand, for lower concentrations of mNAM, PL, PLP and 
MMA we observed that the LFHC-diet trended to be most effective, but for lower 
concentrations of glycine the VHFLC-diet appeared to be slightly more effective (Figure 3). 
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No particular pattern was observed for riboflavin, NAM and serine (Figure 3). Previous 
studies in animals have reported markedly increased plasma concentrations of DMG, glycine, 
mNAM, PL, PLP and MMA following activation of PPARα. In line with the previous studies 
with the exception of DMG and glycine, higher PPARα-activity, as reflected by higher 
concentrations of mNAM, PL, PLP and MMA, might suggest a beneficial effect of following 
a high-fat diet for weight loss. On the contrary, lower PPARα-activity, as reflected by lower 
concentrations of the above-mentioned metabolites might suggest that a low-fat diet would 
lead to larger weight loss. However, the observed trends for the metabolites suggested to 
reflect PPARα-activity were not consistent as DMG and glycine pointed in the opposite 
direction. 
 
Not observing consistent trends in terms of which diet would be most effective for 
metabolites proposed to reflect PPARα-activity could be due to several factors. First of all, 
the metabolites suggested to reflect PPAR-activity were based on studies in rodents treated 
with PPARα-agonists and it has not been tested whether these findings extrapolate to humans. 
Hence, whether these metabolites represent PPARα-activity in humans is uncertain. In 
addition, both the studies in rodents used PPARα agonists with high affinities for PPARα 
which may have led to more marked changes in the concentration of the metabolites as 
opposed to what one might observe naturally such as in our study where no such agonists 
were used. In addition, several differences in PPARα-activation have been observed between 
rodents and humans. For example, the human liver contains smaller amounts of PPARα 
compared to rodent liver and studies have also found evidence that human liver cells are less 
sensitive to PPARα-activation when compared to mice (122, 123). Furthermore, continuous 
administration of PPARα-agonists induces liver carcinogenesis in rodents, but the same 
effects have not been observed in humans which further suggests that the effects of PPARα-
activation differs between humans and rodents (124). Altogether, as the metabolites 
previously suggested to reflect PPARα-activity pointed in somewhat different directions it is 
difficult to conclude whether endogenous PPARα-activity actually influence weight loss 
response to diets differing in fat- and carbohydrate content as it could be that these 
metabolites does not in fact represent PPARα-activity in humans. However, measuring some 
of these metabolites could nevertheless have potential in terms of identifying who will 
respond to each of the diets as will be discussed in the following paragraph.  
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4.2.2 Weight loss response to the diets according to metabolic profile  
Despite not observing consistent patterns for the metabolites proposed to reflect PPARα-
activity in terms of diet effectiveness, several of the metabolites did however demonstrate 
differential weight loss responses to the two diets depending on high- or low concentrations.  
This further makes it possible to suggest a metabolic profile of those who may potentially 
benefit from following a LFHC-diet and those who may be most responsive to a VHFLC-diet. 
Our results suggest that the metabolic profile of those who potentially will benefit most from 
following a VHFLC-diet in terms of weight loss to be characterized by lower concentrations 
of glycine and higher concentrations of homocysteine, sarcosine, PL, PLP, PA and MMA 
(Figure 3). On the contrary, the metabolic profile of those who may potentially benefit more 
from following a LFHC-diet in terms of weight loss was observed to be characterized by 
lower concentrations of homocysteine, sarcosine, mNAM, PL, PLP, PA and MMA and higher 
concentrations of cystathionine, betaine and glycine (Figure 3). 
 
Measuring all of these metabolites in order to identify certain metabolic profiles which can be 
used to stratify individuals to the most effective diet might require too comprehensive 
analyses. However, there may be a potential combination of some of these metabolites which 
can be used for this purpose. For example, PL, PLP and MMA demonstrated the same trends 
in terms of which diet was more effective depending on higher or lower concentrations. 
Further, these metabolites were also observed to be positively intercorrelated (Figure 2), 
which may imply that measuring these metabolites in combination can be used as a combined 
biomarker to stratify individuals to the most effective diet according to their metabolic profile. 
However, considering the exploratory nature of this study and not least the small sample size, 
the observed patterns and suggested metabolic profiles should be interpreted with caution as it 
is not possible to rule out random variation as an explanation.  
 
4.2.3 Comparison of the observed trends with studies using glycemic markers  
To investigate whether the trends we observed pointed in the same direction as previous 
studies using markers of glycaemic status to predict weight loss response to diets differing in 
carbohydrate- and fat-content, we calculated spearman correlations between all metabolites at 
baseline as well as markers of glycaemic status (Figure 2). The markers of glycaemic status 
were glucose, HbA1c, HOMA1-IR and insulin. High concentrations of these markers indicate 
a reduced glucose tolerance and insulin sensitivity whereas lower concentrations indicate a 
better glucose tolerance and insulin sensitivity. As mentioned, previous studies have reported 
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a low-fat, high-carbohydrate diet to be most effective for weight loss among obese individuals 
with normal glucose tolerance and insulin sensitivity and a high-fat, low-carbohydrate diet to 
be the most effective diet for obese individuals with a reduced glucose tolerance and insulin 
resistance (47, 48), although a third study suggested that there might be additional sub-groups 
among those with reduced glucose tolerance which might respond differently depending on 
whether fasting insulin concentrations are high or low (49). However, in terms of previous 
findings, we would expect the metabolites that were positively correlated with markers of 
glycaemic status to trend towards a greater weight loss following the VHFLC-diet when 
concentrations were high and conversely the LFHC-diet to trend towards being most effective 
when concentrations were in the lower range. On the contrary, we would expect the 
metabolites that were negatively correlated with markers of glycaemic status to trend towards 
a greater weight loss following the LFHC-diet when concentrations were high and the 
VHFLC-diet to trend towards being most effective when concentrations were lower. 
 
In the current study, the metabolites that were observed to be most strongly correlated with 
markers of glycaemic status were DMG, cystathionine, mNAM and glycine (Figure 2). DMG 
and cystathionine were both positively correlated with all markers of glycaemic status and 
trended towards a greater weight loss following the LFHC-diet when concentrations were 
high (Figure 2 and 3). Furthermore, mNAM was negatively correlated with all markers of 
glycaemic status and the VHFLC-diet trended towards being most effective for weight loss 
when concentrations were high and conversely the LFHC-diet to be most effective when 
concentrations were lower (Figure 2 and 3). Glycine was also negatively correlated with all 
markers of glycaemic status except glucose, and high concentrations trended towards a 
slightly greater weight loss following the LFHC-diet whereas low concentrations 
demonstrated a marginal greater weight loss following the VHFLC-diet (Figure 2 and 3).  
 
In summary, most of the trends we observed did not point in the same direction as previous 
studies using markers of glycaemic status to predict the weight loss response to diets with 
different fat- and carbohydrate content. In fact, it was only glycine that pointed in the same 
direction as previous studies (47, 48). Nevertheless, lower plasma glycine levels have been 
observed in individuals with insulin resistance and diabetes mellitus type 2, and improvement 
of insulin resistance have been associated with increases in plasma glycine concentrations 
which further supports the observed correlation between glycine and markers of glycaemic 
status in this study (125). Interestingly, although the observed trends for DMG and 
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cystathionine were inconsistent with our assumptions based on two of the studies using 
glycaemic status (47, 48), the observed trends were however in line with the findings of 
Hjorth et al. (49) which reported that individuals with reduced glucose tolerance and high 
insulin lost more weight following a LFHC-diet. This further supports the implications of 
additional sub-groups responding differently among those with reduced glucose tolerance 
depending on high- or low fasting insulin concentrations.  
 
It is important to note that the extreme outliers that were removed from the data visualization 
plot were included in the correlation analysis which might have impacted the observed 
correlations. However, we used the Spearman rank correlation instead of the Pearson 
correlation which is based on ranks rather than the actual values and thus less sensitive to the 
impact of extreme values, although one cannot rule out that this might have affected our 
results. Lack of observing similar trends between the studies might also be due to other 
factors. For example, the studies using glycemic markers included both genders and differed 
in follow-up time compared to this study. In addition, although all the studies used glycemic 
markers as predictors of weight loss response to a high-fat vs. low-fat diet, the dietary 
composition in terms of the amount of fat, carbohydrates and protein differed compared to our 
study which might also have had an effect on the results.  
 
4.2.4 Potential of personalized nutrition  
The large inter-individual variation in weight loss response to dietary interventions counteract 
the belief that one diet fits all and further support the concept and need for more personalized 
nutritional strategies to achieve and maintain weight loss. As mentioned, the ultimate goal of 
personalized nutrition is to issue unique dietary advice to each individual on the basis of 
information on dietary intake and habits, physical activity, genetics, metabolomics and 
microbiota among others. However, such an in-depth and personalized approach may not be 
realistic nor feasible in a public health perspective as it requires high-cost and very 
comprehensive analyses to provide tailored advice to a single individual. In addition, 
considering the high number of people suffering from overweight and obesity in the world 
such a personalized nutrition approach would have to be implemented at a large scale to have 
any effect in the broader picture. Moreover, it might actually contribute to increased health 
disparities by benefitting those who can afford such personalized treatment.  
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A more feasible and less expensive personalized nutrition approach which may benefit a 
larger proportion of the population may be to tailor dietary advice to stratified groups with 
similar characteristics and traits beyond age and gender. Considering the many technologies 
available to study the relationship between biological characteristics and the response to diets, 
it might be possible to identify easily measurable factors or characteristics able to identify 
such subgroups. These characteristics may be used to discriminate between those who will 
respond to a certain diet and those who will have more benefit by following another type of 
diet. In the current study we studied a set of metabolites at baseline to investigate whether 
measuring any of these might be used to predict the inter-individual differences in weight loss 
response to a LFHC- or a VHFLC-diet. Although we did not observe strong evidence for 
interactions between our candidate biomarkers and response to the diets, some interesting 
trends were observed, which should be further explored in larger data sets. Notably, our 
approach was targeted to specific metabolic pathways, and hence we only included a limited 
number of metabolites. Expanding the analyses to include other metabolic pathways could 
have led to the identification of other metabolites able to predict the most effective diet for 
weight loss. Nevertheless, future similar studies using targeted metabolomics might be able to 
replicate our findings as well as identify other metabolites able to predict weight loss response 
to different diets. As mentioned, if several metabolites point towards a beneficial effect of 
following a certain diet over another then it might be possible to construct a combined 
biomarker able to stratify individuals to the most effective diet according to their respective 
metabolic profile.  
 
4.2.5 Adherence  
One common assumption in personalized nutrition is that the more we are able to measure in 
terms of factors which may cause us to respond differently to dietary interventions, the more 
effective and better the outcome following the personalized dietary advice will be. However, 
personalized or not, in order for a certain diet or nutritional recommendation to be effective 
for weight loss it has to lead to a negative energy balance and the individuals receiving the 
advice actually has to adhere to the diet or recommendations they receive both in the short 
and in the long term. As mentioned, lack of adherence to assigned weight loss diets, 
especially in the long-term, can be a problem for individuals trying to lose weight and not 
least maintain the weight loss. Essentially, the challenge with diets in terms of achieving and 
maintaining weight loss is getting individuals to actually make lasting changes in dietary 
behaviour, and the question is whether personalized nutrition advice to a greater extent 
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improve adherence and contribute to lasting changes in dietary habits compared to general 
nutrition advice. It has been shown that informing individuals of having an increased genetic 
susceptibility to develop obesity does increase their readiness to control their body weight 
(126). However, this alone was not sufficient to alter dietary behaviour, potentially because it 
may give the impression that overweight or obesity is genetically determined, and hence less 
controllable as opposed to if it was solely a result of environmental factors. Some studies have 
investigated whether receiving personalized nutrition advice is more effective than standard 
dietary advice in terms of changing dietary habits. Interestingly, one study found that the 
participants were more likely to change their dietary behaviour when receiving the 
personalized nutrition advice compared to general nutrition recommendations, but the 
addition of phenotypic or genotypic information did not contribute to further changes in 
dietary behaviour (127). Although this study did not investigate the effectiveness of 
personalized nutrition advice for changing dietary habits beyond six months, which is 
important in terms of achieving long term weight loss and maintenance, it does provide proof-
of-concept that receiving personalized dietary advice may improve adherence.  
 
However, it is important to note that although one might be able to identify certain factors 
which can predict which diet an individual in theory will be most responsive to, it does not 
necessarily mean that this diet will be the most effective in practice. Food preferences and 
other contextual factors such as the family and social situation must always be considered. 
For example, an individual who in theory will respond best on a high-carbohydrate diet might 
not prefer or like high-carbohydrate foods such as grains or legumes or vice versa, which 
further may make it difficult to implement and adhere to the recommended diet. Moreover, it 
might also be difficult to implement the necessary dietary changes in family or social settings. 
Therefore, it should be emphasized that weight loss can be achieved via different dietary 
approaches, and that long-term adherence is the key to successful weight loss and 
maintenance regardless of which approach is chosen (128).   
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5 Conclusions and future perspectives  
  
In this study, we did not observe strong associations between weight loss and baseline plasma 
concentrations of metabolites related to one-carbon metabolism and markers of B-vitamin 
status. However, we did observe differential trends in weight loss response according to diet 
type and baseline plasma concentration of several of the metabolites. The findings indicate 
that the VHFLC-diet produce larger weight loss when concentrations of glycine are lower and 
concentrations of homocysteine, sarcosine, PL, PLP, PA and MMA are higher, while the 
LFHC-diet was superior when concentrations of homocysteine, sarcosine, mNAM, PL, PLP, 
PA and MMA were lower and the concentrations of cystathionine, betaine and glycine were 
higher. Of the metabolites previously suggested to reflect PPARα-activity, we observed that 
mNAM, PL, PLP and MMA demonstrated similar trends in terms of which diet was more 
effective according to higher or lower concentrations, but glycine and DMG demonstrated 
opposite trends. To further explore whether any of these metabolites can be used to tailor 
dietary weight loss advice to the individual, a first step would be to perform similar studies in 
other existing dietary intervention trials. Future studies with larger sample sizes could provide 
important insights as to which of the metabolites, if any, could be used to differentiate 
between individuals who will respond to either one of the diets. In addition, if a certain set of 
metabolites exhibit similar patterns, these might have the potential to be used as a combined 
biomarker able to stratify individuals to the most effective diet according to their respective 
metabolic profile. 
 
Whether or not the personalized nutrition approach based on metabolic profiling will 
revolutionize the management of overweight and obesity and contribute to long-term 
sustained weight loss is still too early to tell. To date, most of the evidence for a beneficial 
effect of personalized nutrition is based on retrospective or observational studies where 
reproducibility is low (129). In addition, although knowledge on the factors responsible for 
the often-observed inter-individual variation to diets or other dietary interventions is 
increasing there is still a lot that is currently unknown and not least about the interaction 
between these factors. To confirm whether analyses of metabolites, genetics or other factors 
can predict weight loss response to diets and moreover that personalized nutrition advice 
based on such measurements are more effective in changing dietary behaviour than general 
nutrition recommendations, it is of importance that the most promising factors are tested 
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